Literature DB >> 28446667

Disparate Contributions of Human Retrovirus Capsid Subdomains to Gag-Gag Oligomerization, Virus Morphology, and Particle Biogenesis.

Jessica L Martin1,2, Luiza M Mendonça1,3, Isaac Angert1,4, Joachim D Mueller1,4, Wei Zhang1,3,5, Louis M Mansky6,2,3,7,8.   

Abstract

The capsid domain (CA) of the retroviral Gag protein is a primary determinant of Gag oligomerization, which is a critical step for immature Gag lattice formation and virus particle budding. Although the human immunodeficiency virus type 1 (HIV-1) CA carboxy-terminal domain (CTD) is essential for CA-CA interactions, the CA CTD has been suggested to be largely dispensable for human T-cell leukemia virus type 1 (HTLV-1) particle biogenesis. To more clearly define the roles of the HTLV-1 CA amino-terminal domain (NTD) and CA CTD in particle biogenesis, we generated and analyzed a panel of Gag proteins with chimeric HIV-1/HTLV-1 CA domains. Subcellular distribution and protein expression levels indicated that Gag proteins with a chimeric HIV-1 CA NTD/HTLV-1 CA CTD did not result in Gag oligomerization regardless of the parent Gag background. Furthermore, chimeric Gag proteins with the HTLV-1 CA NTD produced particles phenotypically similar to HTLV-1 immature particles, highlighting the importance of the HTLV-1 CA NTD in HTLV-1 immature particle morphology. Taken together, these observations support the conclusion that the HTLV-1 CA NTD can functionally replace the HIV-1 CA CTD, but the HIV-1 CA NTD cannot replace the HTLV-1 CA CTD, indicating that the HTLV-1 CA subdomains provide distinct contributions to Gag-Gag oligomerization, particle morphology, and biogenesis. Furthermore, we have shown for the first time that HIV-1 and HTLV-1 Gag domains outside the CA (e.g., matrix and nucleocapsid) impact Gag oligomerization as well as immature particle size and morphology.IMPORTANCE A key aspect in virus replication is virus particle assembly, which is a poorly understood process for most viruses. For retroviruses, the Gag structural protein is the primary driver of virus particle biogenesis, and the CA CTD is the primary determinant of Gag-Gag interactions for HIV-1. In this study, the HTLV-1 capsid amino-terminal domain was found to provide distinct contributions to Gag-Gag oligomerization, particle morphology, and biogenesis. This study provides information that will aid efforts for discovery of therapeutic targets for intervention.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Gag; morphology; oligomerization; retrovirus; virus assembly

Mesh:

Substances:

Year:  2017        PMID: 28446667      PMCID: PMC5487576          DOI: 10.1128/JVI.00298-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Entropic switch regulates myristate exposure in the HIV-1 matrix protein.

Authors:  Chun Tang; Erin Loeliger; Paz Luncsford; Isaac Kinde; Dorothy Beckett; Michael F Summers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

2.  Gag localization and virus-like particle release mediated by the matrix domain of human T-lymphotropic virus type 1 Gag are less dependent on phosphatidylinositol-(4,5)-bisphosphate than those mediated by the matrix domain of HIV-1 Gag.

Authors:  Jingga Inlora; Vineela Chukkapalli; David Derse; Akira Ono
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

3.  Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.

Authors:  M A Vodicka; W C Goh; L I Wu; M E Rogel; S R Bartz; V L Schweickart; C J Raport; M Emerman
Journal:  Virology       Date:  1997-06-23       Impact factor: 3.616

4.  Distinct Particle Morphologies Revealed through Comparative Parallel Analyses of Retrovirus-Like Particles.

Authors:  Jessica L Martin; Sheng Cao; Jose O Maldonado; Wei Zhang; Louis M Mansky
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

5.  The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability.

Authors:  Jiyang Jiang; Sherimay D Ablan; Suchitra Derebail; Kamil Hercík; Ferri Soheilian; James A Thomas; Shixing Tang; Indira Hewlett; Kunio Nagashima; Robert J Gorelick; Eric O Freed; Judith G Levin
Journal:  Virology       Date:  2011-10-26       Impact factor: 3.616

6.  Efficient assembly of an HIV-1/MLV Gag-chimeric virus in murine cells.

Authors:  B K Chen; I Rousso; S Shim; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

7.  Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switch.

Authors:  Siddhartha A K Datta; Zhuojun Zhao; Patrick K Clark; Sergey Tarasov; Jerry N Alexandratos; Stephen J Campbell; Mamuka Kvaratskhelia; Jacob Lebowitz; Alan Rein
Journal:  J Mol Biol       Date:  2006-10-26       Impact factor: 5.469

8.  Role of the nucleocapsid domain in HIV-1 Gag oligomerization and trafficking to the plasma membrane: a fluorescence lifetime imaging microscopy investigation.

Authors:  Salah Edin El Meshri; Denis Dujardin; Julien Godet; Ludovic Richert; Christian Boudier; Jean Luc Darlix; Pascal Didier; Yves Mély; Hugues de Rocquigny
Journal:  J Mol Biol       Date:  2015-01-30       Impact factor: 5.469

9.  Characterization of the invariable residue 51 mutations of human immunodeficiency virus type 1 capsid protein on in vitro CA assembly and infectivity.

Authors:  Samir Abdurahman; Masoud Youssefi; Stefan Höglund; Anders Vahlne
Journal:  Retrovirology       Date:  2007-09-28       Impact factor: 4.602

10.  Live-cell observation of cytosolic HIV-1 assembly onset reveals RNA-interacting Gag oligomers.

Authors:  Jelle Hendrix; Viola Baumgärtel; Waldemar Schrimpf; Sergey Ivanchenko; Michelle A Digman; Enrico Gratton; Hans-Georg Kräusslich; Barbara Müller; Don C Lamb
Journal:  J Cell Biol       Date:  2015-08-17       Impact factor: 10.539

View more
  8 in total

1.  Human T-cell leukemia virus type 1 Gag domains have distinct RNA-binding specificities with implications for RNA packaging and dimerization.

Authors:  Weixin Wu; Joshua Hatterschide; Yu-Ci Syu; William A Cantara; Ruth J Blower; Heather M Hanson; Louis M Mansky; Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2018-09-14       Impact factor: 5.157

2.  Solution Conformation of Bovine Leukemia Virus Gag Suggests an Elongated Structure.

Authors:  Dominic F Qualley; Sarah E Cooper; James L Ross; Erik D Olson; William A Cantara; Karin Musier-Forsyth
Journal:  J Mol Biol       Date:  2019-02-04       Impact factor: 5.469

3.  Molecular Biology and Diversification of Human Retroviruses.

Authors:  Morgan E Meissner; Nathaniel Talledge; Louis M Mansky
Journal:  Front Virol       Date:  2022-06-02

4.  Critical Role of the Human T-Cell Leukemia Virus Type 1 Capsid N-Terminal Domain for Gag-Gag Interactions and Virus Particle Assembly.

Authors:  Jessica L Martin; Luiza M Mendonça; Rachel Marusinec; Jennifer Zuczek; Isaac Angert; Ruth J Blower; Joachim D Mueller; Juan R Perilla; Wei Zhang; Louis M Mansky
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 5.  Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs.

Authors:  Chinh Tran-To Su; Darius Wen-Shuo Koh; Samuel Ken-En Gan
Journal:  Molecules       Date:  2019-09-06       Impact factor: 4.411

Review 6.  Structure, Function, and Interactions of the HIV-1 Capsid Protein.

Authors:  Eric Rossi; Megan E Meuser; Camille J Cunanan; Simon Cocklin
Journal:  Life (Basel)       Date:  2021-01-29

7.  Gag-Gag Interactions Are Insufficient to Fully Stabilize and Order the Immature HIV Gag Lattice.

Authors:  Ipsita Saha; Benjamin Preece; Abby Peterson; Haley Durden; Brian MacArthur; Jake Lowe; David Belnap; Michael Vershinin; Saveez Saffarian
Journal:  Viruses       Date:  2021-09-28       Impact factor: 5.048

Review 8.  Structural Analysis of Retrovirus Assembly and Maturation.

Authors:  Anna-Sophia Krebs; Luiza M Mendonça; Peijun Zhang
Journal:  Viruses       Date:  2021-12-29       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.